Anteris Technologies Global Corp. (AVR)

Market Cap	200.88M
Revenue (ttm)	2.48M
Net Income (ttm)	-83.93M
Shares Out	36.06M
EPS (ttm)	-2.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	262,918
Open	5.78
Previous Close	5.82
Day's Range	5.59 - 6.43
52-Week Range	2.34 - 8.79
Beta	0.74
Analysts	Strong Buy
Price Target	16.50 (+188.97%)
Earnings Date	Nov 16, 2025

About AVR

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for s...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Dec 13, 2024
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: AVR
• Website: https://anteristech.com

Financial Performance

In 2024, AVR's revenue was $2.70 million, a decrease of -1.17% compared to the previous year's $2.74 million. Losses were -$76.29 million, 65.8% more than in 2023.

Financial numbers in USD

Analyst Summary

According to 4 analysts, the average rating for AVR stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 188.97% from the latest price.

Price Target

$16.5

(188.97% upside)

Analyst Consensus: Strong Buy